A Study of Lasmiditan in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it by comparing the results of healthy elderly participants to those of healthy young participants. The tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. This study will last up to approximately 19 days, not including screening. This study requires either one (Group 2) or two (Group 1) stays at the clinic each of at least four days/three nights. Participants will return for a follow-up seven days after last dose of study drug. Screening is required within 28 days prior to Day 1. This study is for research purposes only and is not intended to treat any medical condition.

Key facts

Study ID

NCT03182920

Run by

Eli Lilly and Company

People needed

35

Starts

2017-06-16

Expected to finish

2017-08-14

Last updated by the study team

2020-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Are overtly healthy males or females, as determined by medical history and physical examination.
• Have a body mass index (BMI) of 19 to 35 kilograms per meter squared (kg/m²) inclusive, at the time of screening.

You may not qualify if…

• Have known allergies to lasmiditan, related compounds or any components of the formulation.
• Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.
• Show evidence of active renal disease or estimated glomerular filtration rate (eGFR) less than 60 milliliter per minute (mL/min) per 1.73 m².
• Show evidence of or positive serology for human immunodeficiency virus (HIV) infection, hepatitis B or C.
• Are women with a positive pregnancy test or women who are lactating.
• Have a clinically significant abnormality in the neurological examination.
• Have a history of syncope, presyncopy, uncontrolled vertigo, postural dizziness, or at risk for falls, as judged to be clinically significant by the investigator.
• Have orthostatic hypotension with or without dizziness and/or syncope at screening or Day -1 upon repeat testing, or a history of it.

Where it is running

• Covance Daytona Beach — Daytona Beach, Florida, United States
• Covance Evansville — Evansville, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.